Literature DB >> 3663559

Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections.

J S Elston1.   

Abstract

One hundred and one patients with idiopathic blepharospasm have been treated with injections of botulinum toxin A into the orbicularis oculi. Ten had previously had facial nerve avulsions and responded well, normal visual function being restored in the majority (7/10) for an average of 14 weeks. Without prior surgical treatment the response was more variable, but 71/91 regained normal or near normal vision. Older patients, those with a family history of the condition, and those without oromandibular dystonia responded slightly better. The severity of the blepharospasm, the length of the history, and spontaneous resolution of an episode of focal dystonia in the past had no influence on the outcome. Results were poor in the presence of an associated neurological disorder. Side effects, particularly a temporary partial ptosis, were common but were well tolerated. The average duration of improvement was eight weeks in men, nine in women, and there was no evidence of any increase in duration after multiple injections. Eighty nine patients continued with injections, 11 opted for surgical treatment, and one resumed drugs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663559      PMCID: PMC1041270          DOI: 10.1136/bjo.71.9.664

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  13 in total

1.  Essential blepharospasm.

Authors:  A C Bird; W I McDonald
Journal:  Trans Ophthalmol Soc U K       Date:  1975-07

2.  Changes in the electron microscopic structure of slow and fast skeletal muscle fibres of the mouse after the local injection of botulinum toxin.

Authors:  L W Duchen
Journal:  J Neurol Sci       Date:  1971-09       Impact factor: 3.181

3.  An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse.

Authors:  L W Duchen
Journal:  J Neurol Sci       Date:  1971-09       Impact factor: 3.181

4.  Absence of antibody production in patients treated with botulinum A toxin.

Authors:  A W Biglan; R Gonnering; L B Lockhart; B Rabin; F H Fuerste
Journal:  Am J Ophthalmol       Date:  1986-02-15       Impact factor: 5.258

5.  Pharmacologic weakening of extraocular muscles.

Authors:  A B Scott; A Rosenbaum; C C Collins
Journal:  Invest Ophthalmol       Date:  1973-12

6.  Choline for blepharospasm.

Authors:  B Skarf; J A Sharpe
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245

7.  Treatment of blepharospasm with botulinum toxin. A preliminary report.

Authors:  B R Frueh; D P Felt; T H Wojno; D C Musch
Journal:  Arch Ophthalmol       Date:  1984-10

8.  Observations on the action of type A botulinum toxin on frog neuromuscular junctions.

Authors:  D A Boroff; J del Castillo; W H Evoy; R A Steinhardt
Journal:  J Physiol       Date:  1974-07       Impact factor: 5.182

9.  Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients.

Authors:  J Jankovic; J Ford
Journal:  Ann Neurol       Date:  1983-04       Impact factor: 10.422

10.  Blepharospasm surgery. An anatomical approach.

Authors:  W N Gillum; R L Anderson
Journal:  Arch Ophthalmol       Date:  1981-06
View more
  9 in total

1.  Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in 37 patients.

Authors:  W Poewe; L Schelosky; B Kleedorfer; F Heinen; M Wagner; G Deuschl
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

2.  A new variant of blepharospasm.

Authors:  J S Elston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

3.  Effect of treatment with botulinum toxin on spasticity.

Authors:  T K Das; D M Park
Journal:  Postgrad Med J       Date:  1989-04       Impact factor: 2.401

4.  Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years.

Authors:  J A Mauriello; S Dhillon; T Leone; B Pakeman; R Mostafavi; M C Yepez
Journal:  Br J Ophthalmol       Date:  1996-12       Impact factor: 4.638

5.  Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease.

Authors:  J M Olver
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

6.  Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years.

Authors:  J A Mauriello; J Aljian
Journal:  Br J Ophthalmol       Date:  1991-12       Impact factor: 4.638

Review 7.  Botulinum Toxin in Movement Disorders: An Update.

Authors:  Charenya Anandan; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2021-01-08       Impact factor: 4.546

8.  Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review.

Authors:  Laura M Scorr; Hyun Joo Cho; Gamze Kilic-Berkmen; J Lucas McKay; Mark Hallett; Christine Klein; Tobias Baumer; Brian D Berman; Jeanne S Feuerstein; Joel S Perlmutter; Alfredo Berardelli; Gina Ferrazzano; Aparna Wagle-Shukla; Irene A Malaty; Joseph Jankovic; Steven T Bellows; Richard L Barbano; Marie Vidailhet; Emmanuel Roze; Cecilia Bonnet; Abhimanyu Mahajan; Mark S LeDoux; Victor S C Fung; Florence C F Chang; Giovanni Defazio; Tomaso Ercoli; Stewart Factor; Ted Wojno; H A Jinnah
Journal:  Dystonia       Date:  2022-05-16

9.  Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.

Authors:  Jin Sook Yoon; Jae Chan Kim; Sang Yeul Lee
Journal:  Korean J Ophthalmol       Date:  2009-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.